Добірка наукової літератури з теми "Drug repurposing against COVID-19"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Drug repurposing against COVID-19".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Drug repurposing against COVID-19"
Mohate, Pratiksha, and Madhav D. Zade. "REVIEW ON DRUG REPURPOSING DRUG USEFUL AGAINST COVID-19." International Journal of Engineering Applied Sciences and Technology 5, no. 2 (June 30, 2020): 449–55. http://dx.doi.org/10.33564/ijeast.2020.v05i02.074.
Повний текст джерелаRodrigues, Liliana, Renata Bento Cunha, Tatiana Vassilevskaia, Miguel Viveiros, and Celso Cunha. "Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates." Molecules 27, no. 9 (April 23, 2022): 2723. http://dx.doi.org/10.3390/molecules27092723.
Повний текст джерелаKhataniar, Ankita, Upasana Pathak, Sanchaita Rajkhowa, and Anupam Nath Jha. "A Comprehensive Review of Drug Repurposing Strategies against Known Drug Targets of COVID-19." COVID 2, no. 2 (January 26, 2022): 148–67. http://dx.doi.org/10.3390/covid2020011.
Повний текст джерелаPuccetti, Matteo, Claudio Costantini, Maurizio Ricci, and Stefano Giovagnoli. "Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics." Pharmaceutics 13, no. 4 (April 5, 2021): 494. http://dx.doi.org/10.3390/pharmaceutics13040494.
Повний текст джерелаWahedi, Hussain Mustatab, and Deeba Amraiz. "Repurposing of Antiviral Drugs for Covid-19 Therapy." Life and Science 1, supplement (December 23, 2020): 10. http://dx.doi.org/10.37185/lns.1.1.151.
Повний текст джерелаKumari, Priyanka, Bikram Pradhan, Maria Koromina, George P. Patrinos, and Kristel Van Steen. "Discovery of new drug indications for COVID-19: A drug repurposing approach." PLOS ONE 17, no. 5 (May 24, 2022): e0267095. http://dx.doi.org/10.1371/journal.pone.0267095.
Повний текст джерелаKumari, Kanchan, and Sandip K Mishra. "Artemisinin and its Derivatives as Repurposing Drug against COVID-19." Acta Scientific Cancer Biology 4, no. 7 (June 22, 2020): 21–23. http://dx.doi.org/10.31080/ascb.2020.04.0237.
Повний текст джерелаParvathaneni, Vineela, and Vivek Gupta. "Utilizing drug repurposing against COVID-19 – Efficacy, limitations, and challenges." Life Sciences 259 (October 2020): 118275. http://dx.doi.org/10.1016/j.lfs.2020.118275.
Повний текст джерелаCiliberto, Gennaro, and Luca Cardone. "Boosting the arsenal against COVID-19 through computational drug repurposing." Drug Discovery Today 25, no. 6 (June 2020): 946–48. http://dx.doi.org/10.1016/j.drudis.2020.04.005.
Повний текст джерелаKolitz, Sarah, Jason Kim, Jenny Zhang, Yoonjeong Cha, Sailaja Battula, Rebecca Kusko, Rajaraman Krishnan, Benjamin Zeskind, and Howard Kaufman. "477 Deep learning to drive COVID-19 rapid drug repurposing." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (November 2020): A509. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0477.
Повний текст джерелаДисертації з теми "Drug repurposing against COVID-19"
Brás, Ana Luzia Alves. "Relatórios de Estágio e Monografia intitulada “Drug Repurposing: Uma oportunidade para as empresas farmacêuticas nacionais”." Master's thesis, 2020. http://hdl.handle.net/10316/93040.
Повний текст джерелаPor drug repurposing (DR) entende-se o recurso a fármacos já aprovados para determinada patologia, com o intuito de identificar novas propriedades, direcionando-os para uma nova indicação terapêutica. Pela existência de dados de segurança, esta abordagem beneficia de custos mais reduzidos e de intervalos de tempo mais curtos. Desta forma, combinam-se medicamentos para criar um tratamento com eficácia superior, comparativamente, ao seu uso em monoterapia, ou investigam-se novos mecanismos de ação. Desta investigação surgem novas indicações terapêuticas, normalmente, na mesma classe farmacológica.Com o intuito de avaliar a hipótese do DR poder ser uma oportunidade para as empresas farmacêuticas nacionais, analisou-se o benefício de colaborações entre organizações, identificou-se uma área emergente e ponderou-se as suas vantagens e desvantagens, bem como os passos futuros a executar.Em 2020, a doença que é provocada pela infeção por coronavírus (COVID-19) tornou-se uma ameaça à saúde pública, a nível mundial. Por este motivo, emergiu a necessidade de uma vacina e / ou um medicamento para que a transmissão da doença estagnasse e para combater a mortalidade que lhe está associada. Nas circunstâncias atuais, o DR surge como alternativa para avançar de forma fugaz na procura por uma solução para travar esta pandemia, ao contrário do que aconteceu com outras antecedentes. Esta ferramenta tem custos reduzidos associados, pelo que pode ser considerada uma oportunidade de investimento por parte das empresas farmacêuticas nacionais.De notar que apesar da existência de inúmeros benefícios, ainda se encontram barreiras por ultrapassar, tais como ampliar as propostas de financiamento, simplificar a conjetura regulamentar e identificar métodos que minimizem erros fortuitos.
Drug repurposing (DR) means the use of drugs already approved for a given pathology, to identify new properties, directing them to a new therapeutic indication. Due to the existence of safety data, this approach benefits from lower costs and shorter time intervals. In this way, drugs are combined to create a treatment with superior efficacy, compared to its use in monotherapy, or new mechanisms of action are investigated. From this research new therapeutic indications usually arise in the same pharmacological class.In order to evaluate the hypothesis that DR may be an opportunity for national pharmaceutical companies, the benefit of collaborations between organizations was analysed, an emerging area was identified and its advantages and disadvantages were pondered, as well as the future steps to be taken.In 2020, the disease caused by coronavirus infection (COVID-19) became a threat to public health worldwide. For this reason, the need for a vaccine and/or a drug has emerged to stagnate the transmission of the disease and to combat the mortality associated with it. In the current circumstances, DR emerges as an alternative to move forward fleetingly in the search for a solution to stop this pandemic, unlike what happened with other precedents. This tool has low associated costs and can therefore be considered an investment opportunity by national pharmaceutical companies.It should be noted that despite the existence of numerous benefits, there are still obstacles to be overcome, such as extending funding proposals, simplifying the regulatory conjecture, and identifying methods to minimise fortuitous errors.
Книги з теми "Drug repurposing against COVID-19"
Drago, Filippo, and Rafael Maldonado, eds. Drug Repurposing for COVID-19 Therapy. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-485-8.
Повний текст джерелаDrago, Filippo, and Rafael Maldonado, eds. Drug Repurposing for COVID-19 Therapy. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-485-8.
Повний текст джерелаSekeres, Mikkael A. Drugs and the FDA. The MIT Press, 2022. http://dx.doi.org/10.7551/mitpress/13620.001.0001.
Повний текст джерелаЧастини книг з теми "Drug repurposing against COVID-19"
Yadav, Monu, Pratibha Dhakla, Rahul Rawat, Mini Dahiya, and Anil Kumar. "Therapeutic Repurposing Approach: New Opportunity for Developing Drugs Against COVID-19." In Drug Repurposing for Emerging Infectious Diseases and Cancer, 543–68. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-5399-6_24.
Повний текст джерелаDwivedi, Shailendra, Aakanksha Rawat, Amit Ranjan, Ruchika Agrawal, Radhieka Misra, Sunil Kumar Gupta, Surekha Kishore, and Sanjeev Misra. "Drug Repurposing and Novel Antiviral Drugs for COVID-19 Management." In COVID-19, 74–95. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003190394-7.
Повний текст джерелаTruong, Anh T. L., Agata Blasiak, Mathias Egermark, and Dean Ho. "AI for Drug Repurposing in the Pandemic Response." In Artificial Intelligence in Covid-19, 59–84. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08506-2_3.
Повний текст джерелаAbdelhady, Aya Salama, Yaseen A. M. M. ElShaier, Mohamed S. Refaey, Ahmed Elsyaed Elmasry, and Aboul Ella Hassanien. "Intelligent Drug Descriptors Analysis: Toward COVID-19 Drug Repurposing." In Studies in Computational Intelligence, 173–91. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-91103-4_10.
Повний текст джерелаTripathi, Manish Kumar, Sujata Sharma, Tej P. Singh, A. S. Ethayathulla, and Punit Kaur. "Computational Intelligence in Drug Repurposing for COVID-19." In Studies in Computational Intelligence, 273–94. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-8534-0_14.
Повний текст джерелаBoutorh, Aicha, Kaouter Marref, and Naamat Ellah Dehiri. "Graph Representation Learning for Covid-19 Drug Repurposing." In Advances in Computing Systems and Applications, 61–72. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-12097-8_6.
Повний текст джерелаAl-Harrasi, Ahmed, Saurabh Bhatia, Tanvir Kabir, Tapan Behl, and Deepak Kaushik. "Role of Drug Repurposing and Natural Products." In Role of Essential Oils in the Management of COVID-19, 61–97. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003175933-6.
Повний текст джерелаO'Reilly, Sophie, Matthew Angeliadis, Ross Murtagh, and Virginie W. Gautier. "Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic." In COVID-19, 39–68. Sheffield, United Kingdom: European Respiratory Society, 2021. http://dx.doi.org/10.1183/2312508x.10024020.
Повний текст джерелаChopra, Simran, Aditya Dahiya, Ashrit Nair, Navneet Sharma, and Rakesh Kumar Sharma. "2-Deoxy-d-Glucose: A Repurposed Drug for COVID-19 Treatment." In Drug Repurposing for Emerging Infectious Diseases and Cancer, 479–500. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-5399-6_20.
Повний текст джерелаVerma, Rohit, Shivani Raj, Umang Berry, C. T. Ranjith-Kumar, and Milan Surjit. "Drug Repurposing for COVID-19 Therapy: Pipeline, Current Status and Challenges." In Drug Repurposing for Emerging Infectious Diseases and Cancer, 451–78. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-5399-6_19.
Повний текст джерелаТези доповідей конференцій з теми "Drug repurposing against COVID-19"
Bastikar, Alpana, Virupaksha Bastikar, Santosh Chhajed, and PramodKumar Gupta. "Targeting SARS-CoV2 Main Protease using HTVS and simulation analysis: A drug repurposing approach against COVID-19." In 6th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2020. http://dx.doi.org/10.3390/ecmc2020-07803.
Повний текст джерелаAdnan, Md, Md Nazim Uddin Chy, Md Riad Chowdhury, and A. T. M. Mostafa Kamal. "<em>In silico</em> virtual screening of known drugs against SARS-CoV-2 3CL protease: A drug repurposing approach for COVID-19." In 6th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2020. http://dx.doi.org/10.3390/ecmc2020-07363.
Повний текст джерела"Drug repurposing for COVID-19 therapy: challenges and opportunities." In Bioinformatics of Genome Regulation and Structure/Systems Biology (BGRS/SB-2022) :. Institute of Cytology and Genetics, the Siberian Branch of the Russian Academy of Sciences, 2022. http://dx.doi.org/10.18699/sbb-2022-198.
Повний текст джерелаAqeel, Imra, Sadia Zafar, Muhammad Bilal, and Abdul Majid. "Drug Repurposing for CoVID-19 Spike Protein through Molecular Docking." In 2022 International Conference on Recent Advances in Electrical Engineering & Computer Sciences (RAEE & CS). IEEE, 2022. http://dx.doi.org/10.1109/raeecs56511.2022.9954482.
Повний текст джерелаWang, Qingyun, Manling Li, Xuan Wang, Nikolaus Parulian, Guangxing Han, Jiawei Ma, Jingxuan Tu, et al. "COVID-19 Literature Knowledge Graph Construction and Drug Repurposing Report Generation." In Proceedings of the 2021 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies: Demonstrations. Stroudsburg, PA, USA: Association for Computational Linguistics, 2021. http://dx.doi.org/10.18653/v1/2021.naacl-demos.8.
Повний текст джерелаPacl, H. T., J. L. Tipper, G. D. Holder, R. R. Sevalkar, S. Nadeem, K. C. Chinta, A. Crouse, A. J. C. Steyn, M. Might, and K. S. Harrod. "Identification and Assessment of FDA-Approved Drugs for Repurposing as Single and Combination Therapies Against SARS-CoV-2 Infection." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3767.
Повний текст джерелаRabbani, Naila, Paul John Thornalley, Maryam Al-Motawa, and Mingzhan Xue. "Vulnerabilities of the SARS-Cov-2 Virus to Proteotoxicity – Opportunity for Repurposed Chemotherapy of COVID-19 Infection." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0291.
Повний текст джерелаChowdhury, Md Riad, and Sadia Akter. "<em>In silico </em>screening of therapeutic agents for COVID-19: A drug repurposing approach." In 7th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2021. http://dx.doi.org/10.3390/ecmc2021-11359.
Повний текст джерелаSvitich, Oxana A., N. D. Abramova, I. V. Bisheva, E. A. Khromova, S. A. Skhodova, N. O. Kryukova, I. A. Baranova, et al. "The level of sIgA in nasal secretions and the incidence of complications in hospitalized patients with COVID-19 against an immunotropic drug." In ERS Lung Science Conference 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/23120541.lsc-2022.258.
Повний текст джерелаCunha, Vinícius Gonçalves Portilho, Alda Maria de Sousa Mendonça, Amanda Selvátici dos Santos Dias, and Ketteny de Lima Rodrigues. "Pediatric onset multiple sclerosis: defying disability – a case report." In XIV Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2023. http://dx.doi.org/10.5327/1516-3180.141s1.661.
Повний текст джерела